Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.61

+5.2%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (533)	1/23/2000 3:12:00 PM
From: A.J. Mullen	Read Replies (1) of 52153

Why should competition for the health-care dollar encourage small molecule drugs? I imagine large molecules might cost more to produce, but that those costs are still small compared to R&D. Perhaps with many good drugs coming to market and competing, the effective royalty rate will be depressed, and this would increase the significance of costs production. Is that your reasoning? Wouldn't drugs still compete largely on grounds of effectiveness? If so, the argument that large-molecule drugs are better targeted would suggest they could be the most effective. Or is it a fallacy that large molecule drugs are better targeted? Ashley

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next